133 related articles for article (PubMed ID: 8078295)
1. Urinary bladder cancer: mechanisms of development and progression.
Kroft SH; Oyasu R
Lab Invest; 1994 Aug; 71(2):158-74. PubMed ID: 8078295
[No Abstract] [Full Text] [Related]
2. Pathways of development and progression in bladder cancer: new correlations between clinical observations and molecular mechanisms.
Jones PA; Droller MJ
Semin Urol; 1993 Nov; 11(4):177-92. PubMed ID: 8290824
[No Abstract] [Full Text] [Related]
3. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
4. [Development of bladder cancer chemoprevention].
Dai G; Wang X
Wei Sheng Yan Jiu; 2003 Mar; 32(2):159-62. PubMed ID: 12793013
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic biomarkers in urothelial bladder cancer.
Kim WJ; Kim YJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):259-69. PubMed ID: 19379084
[TBL] [Abstract][Full Text] [Related]
6. Alterations of tumor suppressor genes in bladder cancer.
Cordon-Cardo C; Reuter VE
Semin Diagn Pathol; 1997 May; 14(2):123-32. PubMed ID: 9179973
[TBL] [Abstract][Full Text] [Related]
7. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers.
Habuchi T; Marberger M; Droller MJ; Hemstreet GP; Grossman HB; Schalken JA; Schmitz-Dräger BJ; Murphy WM; Bono AV; Goebell P; Getzenberg RH; Hautmann SH; Messing E; Fradet Y; Lokeshwar VB
Urology; 2005 Dec; 66(6 Suppl 1):64-74. PubMed ID: 16399416
[TBL] [Abstract][Full Text] [Related]
8. Critical appraisal of tumor markers in bladder cancer.
Fradet Y; Cordon-Cardo C
Semin Urol; 1993 Aug; 11(3):145-53. PubMed ID: 8105526
[No Abstract] [Full Text] [Related]
9. Molecular alterations associated with bladder cancer progression.
Sánchez-Carbayo M; Cordon-Cardó C
Semin Oncol; 2007 Apr; 34(2):75-84. PubMed ID: 17382791
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point.
Decensi A; Torrisi R; Bruno S; Costantini M; Curotto A; Nicolò G; Malcangi B; Baglietto L; Bruttini GP; Gatteschi B; Rondanina G; Varaldo M; Perloff M; Malone WF; Bruzzi P
Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1071-8. PubMed ID: 11045790
[TBL] [Abstract][Full Text] [Related]
11. Genetic modeling of human urinary bladder carcinogenesis.
Czerniak B; Li L; Chaturvedi V; Ro JY; Johnston DA; Hodges S; Benedict WF
Genes Chromosomes Cancer; 2000 Apr; 27(4):392-402. PubMed ID: 10719370
[TBL] [Abstract][Full Text] [Related]
12. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
[TBL] [Abstract][Full Text] [Related]
13. The natural history of superficial bladder carcinoma.
Fitzpatrick JM
Semin Urol; 1993 Aug; 11(3):127-36. PubMed ID: 8210834
[No Abstract] [Full Text] [Related]
14. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer.
Kim EJ; Jeong P; Quan C; Kim J; Bae SC; Yoon SJ; Kang JW; Lee SC; Jun Wee J; Kim WJ
Urology; 2005 Jan; 65(1):70-5. PubMed ID: 15667866
[TBL] [Abstract][Full Text] [Related]
15. Ras signal transduction in carcinogenesis and progression of bladder cancer: molecular target for treatment?
Shinohara N; Koyanagi T
Urol Res; 2002 Oct; 30(5):273-81. PubMed ID: 12389114
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic factors and markers used in urothelial carcinoma of the bladder].
Billerey C; Vieillefond A
Ann Pathol; 1999; 19(5 Suppl):S107-9. PubMed ID: 10599469
[No Abstract] [Full Text] [Related]
17. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
Pham HT; Soloway MS
Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
19. Molecular targeting and pharmacogenomics in the management of advanced bladder cancer.
Raghavan D
Cancer; 2003 Apr; 97(8 Suppl):2083-9. PubMed ID: 12673700
[TBL] [Abstract][Full Text] [Related]
20. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
